Major Events - Ying Si Intelligent (03696), Tu Datong (02665), and Changfeng Pharmaceutical (02652) have been included in the Hang Seng Composite Index [1] - Hansoh Pharmaceutical (03692) has received EU approval for the marketing of Amivantamab for monotherapy [1] - Bole Vision Cloud-B (02592) has had its clinical trial application for CBT-199 approved, recognized as safe to proceed [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval in the US for a GLP-1/GIP receptor dual agonist long-acting injection [1] - CSPC Pharmaceutical Group (01093) has also received clinical trial approval in China for Ropivacaine long-acting injection (SYH9089) [1] - Fuhong Hanlin (02696) has received FDA approval for the Phase I clinical trial application of HLX15-SC for the treatment of multiple myeloma [1] Financial Data - Shougang Resources (00639) issued a profit warning, expecting a net profit attributable to shareholders of approximately HKD 600 million to 700 million for the fiscal year 2025 [1] - Shijiazhuang Pharmaceutical Group (02005) issued a profit warning, anticipating a year-on-year decline in net profit attributable to shareholders of approximately 45% to 60% [1] - Goodbaby International (01086) issued a profit warning, expecting a year-on-year decline in net profit of approximately 35% to 45% for 2025 [1] - Suoteng Juchuang (02498) reported continued growth in sales of laser radar products for fiscal year 2025, achieving profitability for the first time in Q4 [1]

Core Viewpoint - The approval of SYH9089 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of postoperative analgesia, addressing a critical clinical need for long-lasting pain relief solutions [1] Group 1: Product Development - The product, SYH9089, is designed to inhibit sodium ion channels in nerve cells, providing reversible blockage of impulse conduction along nerve fibers [1] - It aims to reduce the frequency of administration, fulfilling the continuous pain relief requirements post-surgery and decreasing reliance on opioid medications [1] - The product can extend the duration of analgesia from a single dose to one week, potentially becoming the first ultra-long-acting analgesic in China [1] Group 2: Clinical Research and Safety - Preclinical studies indicate that SYH9089 does not exhibit systemic toxicity or new toxic organ targets, showing significant long-lasting analgesic advantages compared to existing ropivacaine injections [1] - The approved clinical indication for the product is postoperative pain relief, highlighting its potential to meet urgent clinical demands in the ultra-long-acting postoperative analgesia sector [1]

Core Viewpoint - The approval of SYH2082 by the FDA marks a significant advancement for the company in the development of innovative long-acting products in the metabolic field, with potential benefits for obesity management and type 2 diabetes [1][2] Group 1: Product Development - The SYH2082 injection has received FDA approval to conduct clinical trials in the United States [1] - SYH2082 is expected to be a leading long-acting GLP-1/GIP receptor dual agonist, administered once a month, enhancing patient compliance and convenience [1] - The product utilizes the company's long-acting formulation technology platform, achieving sustained weight loss during the dosing interval [1] Group 2: Clinical Benefits - The approved clinical indication is for weight management in individuals with obesity or overweight with at least one weight-related comorbidity [2] - SYH2082 also shows potential for improving blood glucose control in adults with type 2 diabetes, providing additional clinical benefits [2] - Preclinical studies indicate that SYH2082 demonstrates superior efficacy in long-term weight loss and maintenance compared to similar marketed products [1][2] Group 3: Safety and Tolerability - In toxicology studies, SYH2082 exhibited good tolerability with no significant adverse reactions observed [1]

Core Viewpoint - The approval of SYH2082 by the FDA marks a significant milestone for the company in the development of innovative long-acting products in the metabolic field, with potential benefits for obesity management and type 2 diabetes [1][2] Group 1: Product Development - The company has developed SYH2082, a long-acting GLP-1/GIP receptor dual agonist injection, which has received FDA approval for clinical trials in the U.S. [1] - SYH2082 is designed for monthly administration, enhancing patient compliance and convenience [1] - The product utilizes a long half-life modification platform and long-acting formulation technology to achieve sustained weight loss during the dosing interval [1] Group 2: Clinical Benefits - The approved clinical indication for SYH2082 is weight management in individuals with obesity or overweight with at least one weight-related comorbidity [2] - SYH2082 also shows potential for improving blood glucose control in adults with type 2 diabetes, providing additional clinical benefits [2] Group 3: Preclinical and Toxicology Findings - In preclinical studies, SYH2082 demonstrated superior efficacy in long-term weight loss and maintenance compared to similar marketed products, supporting a monthly dosing regimen [1] - Toxicology studies indicated good tolerability for SYH2082, with no significant adverse reactions observed [1]

Core Viewpoint - The approval of SYH9089 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of postoperative analgesia, addressing a critical clinical need for long-lasting pain relief solutions [1] Group 1: Product Development - The SYH9089 injection utilizes a mechanism that inhibits sodium ion channels in nerve cells, providing reversible blockage of impulse conduction along nerve fibers [1] - This product aims to reduce the frequency of administration, fulfilling the continuous pain relief requirements in postoperative settings and decreasing reliance on opioid medications [1] - The long-acting drug delivery technology platform allows for pain relief duration of up to one week from a single administration, potentially making it the first ultra-long-acting analgesic product in China [1] Group 2: Clinical Research and Safety - Preclinical studies indicate that SYH9089 injection does not exhibit systemic toxicity or new toxic organ targets, showing significant long-lasting analgesic advantages compared to existing ropivacaine injections [1] - The approved clinical indication for this product is postoperative pain relief, highlighting its potential to meet urgent clinical demands in the ultra-long-acting postoperative analgesia market [1]

Core Viewpoint - The approval of SYH9089 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of postoperative analgesia, addressing a critical clinical need for long-lasting pain relief solutions [1] Group 1: Product Development - The SYH9089 injection utilizes a mechanism that inhibits sodium ion channels in nerve cells, providing reversible blockage of impulse conduction along nerve fibers [1] - This product aims to reduce the frequency of administration, fulfilling the continuous pain relief requirements in postoperative settings and decreasing reliance on opioid medications [1] - The long-acting drug delivery technology platform allows for pain relief duration of up to one week with a single administration, potentially making it the first ultra-long-acting analgesic in China [1] Group 2: Clinical Research and Safety - Preclinical studies indicate that SYH9089 injection shows no systemic toxicity or new toxic organ targets, demonstrating significant long-lasting analgesic advantages compared to existing ropivacaine injections [1] - The approved clinical indication for this product is postoperative pain relief, highlighting its potential to meet urgent clinical demands in the ultra-long-acting postoperative analgesia market [1]

Core Viewpoint - The approval of SYH2082 by the FDA marks a significant advancement for the company in the development of innovative long-acting products in the metabolic field, with potential benefits for obesity management and type 2 diabetes [1][2] Group 1: Product Development - The GLP-1/GIP receptor dual agonist SYH2082 has received FDA approval to conduct clinical trials in the United States [1] - SYH2082 is designed for once-monthly administration, enhancing patient compliance and convenience [1] - The product utilizes a long-acting formulation technology platform, aiming for sustained weight loss during the dosing interval [1] Group 2: Clinical Benefits - The approved clinical indication for SYH2082 is weight management in individuals with obesity or overweight who have at least one weight-related comorbidity [2] - SYH2082 also shows potential for improving blood glucose control in adults with type 2 diabetes, providing additional clinical benefits [2] Group 3: Efficacy and Safety - Preclinical studies indicate that SYH2082 demonstrates superior efficacy in long-term weight loss and maintenance compared to similar marketed products [1] - Toxicology studies show good tolerability for SYH2082, with no significant adverse reactions observed [1]

CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 – 1 – 本 次 獲 批 的 臨 床 適 應 症 為 肥 胖 或 超 重 合 併 至 少 一 種 體 重 相 關 合 併 症 人 群 的 體 重 管 理 。 此 外，SYH2082亦具備改善成人2型糖尿病（ T2DM ）患者的血糖控制的潛力，帶來額外臨床獲 益。本次臨床試驗的獲批，是本集團在代謝領域創新長效產品佈局的重要成果，為未來更 多創新產品的開發奠定堅實基礎。 承董事會命 石藥集團有限公司 主席 蔡東晨 香港，2026年2月16日 自願公告 GLP -1 / GIP受體雙偏向性激動多肽長效注射液（SYH2082注射液） 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 ...

CSPC PHARMACEUTICAL GROUP LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1093） （於香港註冊成立之有限公司） 承董事會命 石藥集團有限公司 自願公告 羅哌卡因長效注射液（SYH 9089注射液） 在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的羅哌卡因長效注射液（ SYH 9089注射液 ）（「該產品」）已獲得中華人民共和 國國家藥品監督管理局批准，可在中國開展臨床試驗。 該產品可通過抑制神經細胞鈉離子通道，阻斷鈉離子流入神經纖維細胞膜內，從而對沿神 經 纖 維 的 衝 動 傳 導 產 生 可 逆 性 的 阻 滯 ； 亦 能 降 低 給 藥 頻 率 ， 滿 足 臨 床 術 後 的 持 續 鎮 痛 需 求，減少患者對阿片類藥物的依賴，避免持續鎮痛裝置感染 ...

Core Insights - The annual transaction value of China's innovative drug licensing has surpassed $100 billion, marking a nearly tenfold increase over four years, with a total of $137.7 billion in licensing deals signed in 2025 [2] - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, have signed significant agreements with Chinese firms, indicating a strong interest in China's next-generation innovative drug development pipelines [3] - The average transaction size for licensing deals involving Chinese biopharmaceutical companies has significantly increased this year, with an average deal size of $1.3 billion, a 76% increase from 2025 and six times the average size in 2021 [4] Group 1 - In 2025, there were 186 licensing transactions involving Chinese companies, reflecting a growing trend in the biopharmaceutical sector [2] - The average upfront payment for licensing deals this year is $77.7 million, double that of 2025 and three times the average in 2021 [4] - Notable recent agreements include a strategic partnership between Innovent Biologics and Eli Lilly worth $8.85 billion, and a potential $18.5 billion collaboration between AstraZeneca and CSPC Pharmaceutical Group [4] Group 2 - Macquarie Capital predicts that oncology drugs will continue to attract global pharmaceutical companies, highlighting China's strong capabilities in chemical drug development [5] - Multinational companies are increasingly viewing China as a critical part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [5] - Vision Lifesciences reports that China leads the world in specific molecular types, with Chinese companies accounting for nearly 90% of global licensing transactions for antibody-drug conjugates (ADCs) [5]